Oct 30 (Reuters) - Eli Lilly ( LLY ) missed Wall Street

estimates for third-quarter profit on Wednesday, even as demand

for its weight-loss drug soared, hurt by higher manufacturing

and acquisition-related costs.

The company earned $1.18 per share on an adjusted basis for

the quarter ended Sept.30, compared with analysts' average

estimate of $1.47, according to LSEG data.

(Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru;

Editing by Sriraj Kalluvila)